Varying the nicotine content of cigarettes
Other- Altering the nicotine content of the tobacco research cigarettes
Other names: Comparing normal nicotine content (RC1) to very low nicotine content (RC2)
NCT Number: NCT04092387
Despite marked reductions in cigarette smoking in the general population, smoking among economically disadvantaged women has increased. Smoking among women of reproductive age is a particular concern because in addition to the usual health risks, there are additional risks should they become pregnant. A national nicotine reduction policy for cigarettes has considerable potential to reduce tobacco use, dependence, and improve health in this population. Controlled trials in general population samples have demonstrated that reducing the nicotine content in cigarettes can reduce cigarettes per day (CPD), dependence severity, and tobacco toxicant exposure.
The goal of the proposed trial is to experimentally examine whether increasing the availability and appeal of an alternative, non-combusted source of nicotine (e-cigarettes) enhances the effect of altering the nicotine in cigarettes in non-pregnant female cigarette smokers of childbearing age. Additionally, investigators will test whether allowing participants to personalize the flavor of the e-liquid alters any moderating effects their availability may have on tobacco cigarette smoking.
Daily smokers who are female, aged 21-44 years, and have a maximum educational attainment of graduating high school, will be recruited at Johns Hopkins University and the University of Vermont.
Investigators will study two research cigarettes referred to here as Research Cigarettes 1 (RC1) and Research Cigarettes 2 (RC2). One will be a normal nicotine content cigarette and the other a reduced nicotine content cigarette. Investigators will study two e-cigarette conditions referred to here as E-Cigarette Condition 1 (EC1) and E-Cigarette Condition 2 (EC2). Both e-cigarette conditions will involve the same commercially available devices and same nicotine-containing e-liquid, but in one condition that e-liquid will be available only in tobacco flavor while in the other the e-liquid will be available in multiple flavors from which participants can choose three based on personal preference. Participants will be assigned to one of the following four conditions: (1) RC1 only; (2) RC2 only; (3) RC2 + EC1; (4) RC2 + EC2.
Participants will be asked to use only their assigned study products for 16 weeks. Outcome measures include total CPD, craving, withdrawal, psychiatric symptoms, breath carbon monoxide (CO), other biomarkers of tobacco toxicant exposure, and cigarette demand assessed by behavioral economic purchase tasks.
Looking for future studies?
Notify Me21 year–44 year
Female
Interventional
Not applicable
Johns Hopkins University, Baltimore, Maryland, United States
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Other names: Comparing normal nicotine content (RC1) to very low nicotine content (RC2)
Comparing effects of combining RC2 with EC 1 versus EC2
Other names: e-cigarette with only tobacco flavor (EC 1); e-cigarette in multiple flavors ( EC2)
Time frame: 16 weeks
Cigarettes per day will be assessed for use of cigarettes with different nicotine content.
University of Vermont
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05110872
Behavior, Chemically-Induced Disorders
Roanoke, Virginia, United States
View Trial DetailsNCT04090879
Behavior, Chemically-Induced Disorders
Providence, Rhode Island, United States
View Trial DetailsNCT04092101
Behavior, Chemically-Induced Disorders
Baltimore, Maryland, United States
View Trial DetailsNCT04772014
Behavior, Behavior, Addictive
Mannheim, Germany
View Trial Details